相关实验视频

Updated: Jun 19, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

抗脂抗体作为复发性缺血性中风的潜在预后指标

Lina Geng¹, Kai Pan², Yuhuan Xu¹

¹Clinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou City, Hebei Province, China.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

|July 26, 2024

概括

像抗脂抗体 (aPLs) 和抗核抗体 (ANA) /抗ENA这样的自身免疫标志物与复发性缺血性中风有关. 氧化 (HCQ) 可能会减少受影响患者中风复发.

科学领域:

免疫学免疫学免疫学
神经学神经学
心血管医学心血管医学

背景情况:

免疫力显著影响缺血性中风风险,并与自身免疫性疾病有关.
这项研究调查了特定自身抗体对缺血性中风结果的预后影响.

研究的目的:

确定抗脂抗体 (aPLs),抗核抗体 (ANA) 和抗ENA对缺血性中风预后的影响.
评估氧化 (HCQ) 作为这些自身抗体的中风患者的潜在治疗方法.

主要方法:

这是一项为期3年的前性队列研究,对245名缺血性中风患者进行了研究.
在复发性缺血性中风 (RIS) 和非复发性缺血性中风 (nonRIS) 组中评估aPLs (ACA,anti-β2GPI,LA),ANA和anti-ENA.
在42名IS患者中对HCQ进行随机对照试验,具有阳性aPLs + ANA/anti-ENA.

主要成果:

在RIS患者中,ACA IgG,抗β2GPI IgG,LA,和aPLs + ANA/anti-ENA组合的比率更高.
aPLs + ANA/anti-ENA和高血压被确定为中风复发的独立风险因素.
根据自身抗体状态,在36个月内中风严重程度 (NIHSS) 的显著差异.
与对照组相比,HCQ治疗组的复发率较低.

结论:

aPLs和ANA/anti-ENA的共同阳性是复发性缺血性中风的独立预测因素.
在患有这些自身抗体的患者中,HCQ疗法显示出降低缺血性中风复发的潜力.

关键词:

反提取的核抗原自身抗体抗提取的核抗原自身抗体抗核抗体是一种抗核抗体.抗脂抗体是一种抗脂抗体.经常发生的缺血性中风.

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...